If you have been reading about AOD9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-03. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
== History == The earliest written descriptions of thiamine deficiency are from ancient China in the context of Chinese medicine. One of the earliest is by Ge Hong in his book Zhou hou bei ji fang (Emergency Formulas to Keep up Your Sleeve) written sometime during the third century. Hong called the illness by the name jiao qi, which can be interpreted as "foot qi". He described the symptoms to include swelling, weakness, and numbness of the feet. He also acknowledged that the illness could be deadly, and claimed that it could be cured by eating certain foods, such as fermented soybeans in wine. Better known examples of early descriptions of "foot qi" are by Chao Yuanfang (who lived during 550–630) in his book Zhu bing yuan hou lun (Sources and Symptoms of All Diseases) and by Sun Simiao (581–682) in his book Bei ji qian jin yao fang (Essential Emergency Formulas Worth a Thousand in Gold). In the mid-19th century, interest in beriberi steadily rose as the disease became more noticeable with changes in diet in East and Southeast Asia. A steady uptick occurred in medical publications, reaching 181 publications from 1880 and 1889, and hundreds more in the following decades. The link to white rice was clear to Western doctors, but a confounding factor was that some other foods such as meat failed to prevent beriberi, so it could not be easily explained as a lack of known chemicals like carbon or nitrogen. With no knowledge of vitamins, the etiology of beriberi was among the most hotly debated subjects in Victorian medicine.
== Description == The species grows to be about 50 mm, or about 2 inches. This slug has been treated as a model organism and used in studies into classical conditioning, memory consolidation and associative learning, the structure of neural circuits and neural physiology. It has also been used to investigate ultrastructure and anatomy, larval and reproductive ecology, behavioral ecology and pharmacology and toxicology including studies into Beta thymosins. Unfortunately these studies did not differentiate between the three species of Hermissenda.
He was suspicious of the Soviet Union's motives in supporting African liberation movements, relating that "Russia is as imperialistic as America", although he acknowledged that "in the eyes of the Third World they have a cleaner slate". He also acknowledged that the material assistance provided by the Soviets was "more valuable" to the anti-apartheid cause than the "speeches and wrist-slapping" provided by Western governments. He was cautious of the possibility of a post-apartheid South Africa getting caught up in the imperialist Cold War rivalries of the United States and the Soviet Union.
=== Extraction and purification === Throughout history, extraction and purification methods have evolved from standard chromatographic methods to the utilisation of affinity tags. However, the final extraction and purification process undertaken highly depends on the chosen expression system. Please refer to subunit expression and synthesis for more insights.
Sources: en.wikipedia.org
6 August Weather Forecast about weather forecasting in the UK; Swedish Lennart Bengtsson of the European Centre for Medium-Range Weather Forecasts; Alistair Woodroffe and Brian Webster of the Met Office; numerical calculations began in the early 1950s with computers making 10,000 calculations a second but by the mid-1980s it was one billion; Meteosat-2 launched in June 1981; Steven Burke of the London Potato Futures Association; Capt Derek Ralph in a British Caledonian BAC One-Eleven flying to Aberdeen Airport; amateur weatherman Bill Foggitt; the weather centre and Lockheed C-5 Galaxy aircraft at RAF Mildenhall; conservationist Robin Page; narrated by Muriel Gray, directed by John Dollar, made by Uden Associates 13 August Made to Measure, essentially a re-edited, slightly updated edition of the August 1986 episodes on the F1 Ford turbocharged engine, with a few minutes of new content; in May 1987 Peter Collins watches the previous San Marino Grand Prix; Ford Cosworth V6 B187 cars: engine mapping; Dick Scammel, general head of engineering; Martin Walters, chief development engineer; the engine is dismantled, and damage is found; Geoff Goddard, chief racing engine designer; electromagnetic pulses from the engine affected the working of the engine computer circuitry; rogue signals were picked up by the engine computer, so causing erratic fuel injection; French F1 driver Patrick Tambay listens to the sound of the turbo; the turbo pressure would be limited to 2.5 in 1988, before turbos were banned for the 1989 season; the Italian Grand Prix circuit; each team is allowed two sets of qualifying tyres; the tyres on the rear axle warm up before the front axle; the Honda V6 engine could produce 1200 hp; chief designer Rory Byrne, and F1 aerodynamic forces. Narrated mostly by Martin Jarvis and partly by Eleanor Bron 20 August Twang, Bang, Kerang!, about the electric guitar; the Fat Tuesdays night club, and Les Paul; Glenn Wilson of the Institute of Psychiatry in London; Louis Jordan in the late 1940s; Charlie Christian developed the Gibson-ES150; Steve Howe of Yes; Burns London manufacturing guitars; Dave Russell; the body of the guitar was made of maple, a tonewood, and the fretboard of rosewood; the sound originates from the type of wood; Jerry Donohue of Fairport Convention; pickups made by Seymour Duncan; Chet Atkins; Andy Summers of The Police and Every Breath You Take; Francis Dunnery of It Bites, and Once Around the World. Narrated by John Hedges, produced by Patrick Uden, directed by Jeremy Llewellyn-Jones, made by Uden Associates 27 August What Goes Up..., about dismantling the AGR at Sellafield; it featured Tom Marsham CBE FRS (10 November 1923 – 12 October 1989) of UKAEA at Risley, Warrington (Birchwood Park), who was the reactor manager of Calder Hall in 1956. Narrated by Sue Jay, produced by Michael Blakstad, made by Workhouse Productions 3 September Hole in the Sky, about the depletion of the ozone layer, with Sir Bob Watson at NASA; the NERC's British Antarctic Survey had been measuring ozone levels since 1957 at the Halley Research Station, and a team led by Joe Farman noticed a hole in the layer; NASA had not noticed an ozone hole on its Nimbus 7 satellite, although the satellite had picked up all of the data, as Richard Stolarski of the Goddard Space Flight Center found; the ozone hole was caused by the polar vortex over the winter, where air movements outside of Antarctica are trapped, and there is not enough light to form new ozone; some people believed that the 1982 Mexican El Chichón volcanic eruption was to blame; in 1974 F. Sherwood Rowland and Mario Molina of the University of California, Irvine found that some chlorine compounds would destroy ozone by making chlorine monoxide, and both received the 1995 Nobel Prize in Chemistry for this discovery; the Chemical Manufacturers' Association (since 2000 the American Chemistry Council) and the National Science Foundation launched a new atmospheric survey at McMurdo Station, led by Susan Solomon of the Earth System Research Laboratories; Jerry D. Mahlman of the Geophysical Fluid Dynamics Laboratory at Princeton was attempting a computer model of the Antarctic atmosphere; Rafe Pomerance of the World Resources Institute; the greenhouse effect, described by James Hansen of the Goddard Institute for Space Studies, who claimed that the Earth's temperature would be 2 degrees higher by 2000, 3 degrees higher by 2010, and 4 to 7 degrees warmer by 2030; Richard E. Benedick. Directed by Linda Harrar, produced by Paula Apsell, made by WGBH, Uden Associates, Television Trust for the Environment and Sveriges Television. Originally a Nova documentary 24 September Dirty Money, about whether the environment can be cleaned up; the UK's first anti-pollution trade fair in March 1987, attended by William Waldegrave; Father Jim Conlon and Portglenone Abbey in N Ireland, with an anaerobic digester, which saved £1000 a month in gas cost, and the manure was sold for £25,000 a year; Mike Flux of ICI; biologist Paul Johnston of Greenpeace, in Teesside; the River Tees was the second-most polluted in the UK, with Douglas Ord of Northumbrian Water; Ken Murphy, and how Greenpeace attempted to block an effluent pipe near Immingham in March 1985; John Elkington, environmental writer; BioTechnica of Llanishen in Cardiff, reclaiming contaminated land on a former highly polluted gasworks site in Lancashire; Jutta Ditfurth; Hans-Georg Peine of BASF AG, and the Sandoz chemical spill in November 1986 in Switzerland; in 1983, ICI founded the first bioplastic company, called Marlborough Biopolymers, which made polyhydroxy butyrate; Dame Anita Roddick of The Body Shop, who worked with Friends of the Earth; Peter Baylis of the NERC Environmental Satellite Laboratory, which began in 1975, in the University of Dundee's Ewing Building, and largely provided the only UK archive of satellite environmental data. Narrated by Bob Peck, produced by Edward Poulter, directed by David Sharp, made by London Scientific Films 1 October Malltime. A US production, produced by Mike Wallington, made by George Haggerty, made by Kai Productions 8 October Anything You Can Do..., about new robotics; the five houses puzzle; Richard Gregory, professor of neuropsychology at the University of Bristol; Roger Mathias of Plessey Radar and the Multi-function Electronically Scanned Adaptive Radar (MESAR), began in 1982; Henry Thompson and speech recognition at the School of Informatics, University of Edinburgh; Robert Kowalski of the Department of Computing, Imperial College London; Margaret Boden of the University of Sussex; J. Michael Brady; Paul Caplin and robotics; Roy Bottomley of Meiko Scientific, and the transputer, developed in the UK; Plessey Laboratories at the Allen Clark Research Centre, and new chemical compounds for computer chip; logic programming and heuristics; the European Eureka Prometheus Project, an expert system. Narrated by Miriam Margolyes, produced by Michael Blakstad, directed by Catherine Robins, made by Workhouse Productions 22 October Command and Control, the chain of command of nuclear weapons; it featured the Air Force Research Laboratory. Directed by Clive Syddall, made by Twenty Twenty Vision 5 November Earthquake Country, about the San Andreas fault; Robert Wallace, chief scientist of the USGS; the 1906 earthquake caused the tectonic planes to move around seven metres; geologist Grove Karl Gilbert; an earthquake in the middle section of the fault was expected for around 1988; a 5.8 earthquake on 8 June 1934; geologist Kerry Sieh and paleoseismology; if an earthquake took place, coordination would be from the Joint Forces Training Base - Los Alamitos; earthquake engineer George W. Housner of Caltech; structural engineer Ray William Clough; earthquake engineer Luis Estava Maraboto of the Engineering Institute of the National Autonomous University of Mexico. Produced by Arabella Woods, directed by John Tchalenko, made by Red Rooster Films 12 November Nature's Technology, about the different types and the modelling of animal locomotion, and legged robots; robotic hands and bioengineer Stephen Jacobsen of the University of Utah; snake-arm robots; the 1986 Adaptive Suspension Vehicle (ASV) of Ohio State University, a hexapod robot, and Vincent Vohnout; active balance and Marc Raibert; the 1965 Walking Truck of General Electric; static stability and the Odex 1 six-legged robot; biomechanics and Robert McNeill Alexander, Professor of Zoology; WABOT-2 of Waseda University, optical music recognition and the NHK Symphony Orchestra of Japan conducted by Yuzo Toyama. Narrated by Adrienne Posta, directed by David Barlow, produced by Karl Sabbagh, made by InCA 19 November Britain Can Make It?, about making kitchen units in the UK and in Germany; the dual system of apprenticeship in Germany; Sig Prais of the National Institute of Economic and Social Research; the Britain Can Make It exhibition, where the fitted kitchen was first introduced in the UK; the Hungarian designer George Fejer was largely responsible for introducing fitted kitchens; Wolfgang Luckhaus of Poggenpohl of Germany, which also developed the fitted kitchen; in the 1960s the Germans introduced chipboard for kitchen manufacturing, which became industry-standard, with wipe-clean melamine resin facing (MFC); Hilary Steedman of the NIESR, and how the Germans built kitchens to order, whereas British companies simply built kitchens, whether ordered or not; Heal's of London introduced German kitchens to the UK in the early 1970s, in a hausfest; the German SieMatic kitchen company; Doug Gregory started The Symphony Group in 1970 after seeing chipboard, developing flatpack kitchen units, the Germans did not make flatpack kitchens, only assembled kitchens; David Love, buying director of MFI, which was helped by the flatpack revolution, but it was all largely an imitation of German products, and was a mostly standard product range; Symphony introduced computer production control in the 1980s, which the Germans had introduced in the early 1970s - this allowed much more variation of manufacturing to order, which was the main German method; employees of Symphony were largely unskilled, but German workers were largely skilled apprentices, who had passed exams in manufacturing; nearly all of German kitchens were built to order, so needed skilled workers; Walter Siekmann, production manager of Poggenpohl; German furniture manufacture was found in East Westphalia (Ostwestfalen); the Germans believed in more thorough technical training, and sold their products all over the world, but British companies had less-thorough training, and did not sell as worldwide as the Germans. Narrated by John Woodvine, directed by David Habakkuk, made by Riverside Television 26 November At the Edge, about the physical limits placed upon fighter pilots when flying high G capable modern aircraft, such as the F16 and the F18. Pilots are subjected to G-LOC in the Aerospace Medicine centrifuge in San Antonio, Texas. Narrated by Ray Brooks, written, produced and directed by Chris Haws, made by InCA
G protein dependent activation of phospholipase C (PLC) which results in the breakdown of the membrane constituent phospholipid, phosphatidylinositol (4,5)-bisphosphate (PIP2) into inositol (1,4,5)-trisphosphate (IP3) and diacyl glycerol (DAG). IP3 is one of the most effective inducers of Ca2+ increase from cytoplasmic pools and from outside the cell via opening Ca2+ channels. DAG in turn is an inducer of protein kinase C (PKC). Activation of the regulatory small GTPase, RAS. The active RAS can in turn activate RAF, a Ser/Thr kinase. In the next step mitogen-activated protein kinases (MAP kinases) are activated. (Also known as extracellular signal-regulated kinases - ERKs or MAP/ERK kinase (MEK)). As a result of the last step, ERK1 and ERK2 are activated. The phosphorylated forms of ERKs can continue the cascade by triggering activation more interacting kinases which results in altered transcriptional activity in the nucleus. Ligand binding to FPR can also induce the activation of CD38, an ectoenzyme of the surface membrane. As a result of activation NAD+ molecules will enter the cytoplasm. NAD+ is converted into cyclic ADP ribose (cADPR), a second messenger which interacts with ryanodine receptors (RyR) on the surface of the rough endoplasmic reticulum. The overall result of the process is increased cytoplasmic Ca2+ levels via the direct pathway described above and also via indirect pathways such as opening of Ca2+ channels in the cell membrane. The sustained increase of Ca2+ is required for directed migration of the cells.
=== Iron deficiency === One of the causes of iron-deficiency anemia is reduced absorption of iron. Iron absorption can be enhanced through ingestion of vitamin C alongside iron-containing food or supplements. Vitamin C helps to keep iron in the reduced ferrous state, which is more soluble and more easily absorbed. It also chelates iron into a soluble complex. It specifically helps the absorption of non-heme iron, which is found in non-meat sources and absorbed via DMT1.
=== Treatment approaches for primary glaucoma === Primary angle closure glaucoma: Once any symptoms have been controlled, the first line (and often definitive) treatment is laser iridotomy. This may be performed using either Nd:YAG or argon lasers, or in some cases by conventional incisional surgery. The goal of treatment is to reverse and prevent contact between the iris and the trabecular meshwork. In early to moderately advanced cases, iridotomy is successful in opening the angle in around 75% of cases. In the other 25%, laser iridoplasty, medication (pilocarpine), or incisional surgery may be required. Primary open-angle glaucoma: Prostaglandin agonists work by opening uveoscleral passageways. Beta-blockers, such as timolol, work by decreasing aqueous formation. Carbonic anhydrase inhibitors decrease bicarbonate formation from ciliary processes in the eye, thus decreasing the formation of aqueous humor. Parasympathetic analogs are drugs that work on the trabecular outflow by opening up the passageway and constricting the pupil. Alpha 2 agonists (brimonidine, apraclonidine) both decrease fluid production (via inhibition of AC) and increase drainage. A review of people with primary open-angle glaucoma and ocular hypertension concluded that medical IOP-lowering treatment slowed down the progression of visual field loss.
A 2020 review in The Journal of Bone and Joint Surgery (JB&JS) found it remains broadly popular: ≈2⁄3 of people with OI types III and IV (severe OI) have undergone some form of rodding surgery in their lives, at a mean age of 4+1⁄10 and 7+1⁄2 years respectively; one possible explanation for a tendency towards earlier intervention in type III is that one half of affected children could not walk at all without the surgery, as their limbs were more bowed, so surgery was sought sooner. In those with type III OI who had undergone rodding surgery, 79.5% had the femurs and tibias of both legs rodded. The most common form of rods used are intramedullary (IM) rods, some of which, such as the Fassier–Duval IM rod, are telescoping, meaning that they are designed to grow as the child grows, in an attempt to avoid the necessity of revision surgeries. Telescoping IM rods are widely used, and the common Fassier–Duval IM rod is designed to be used to rod the femur, tibia, and humerus. The surgery involves breaking the long bones in between one and three (or more) places, then fixing the rod alongside the bone to keep it straight. While telescoping IM rods are intended to grow along with both the femur and tibia in developing children; surgeons have a preference to use non-telescoping IM rods, such as Rush rods, in the tibia, which grows less comparatively—the JB&JS review found that while 69.7% of femurs were treated with telescoping IM rods, only 36.9% of tibiae were.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.